Invention Grant
- Patent Title: Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
-
Application No.: US16320436Application Date: 2017-07-24
-
Publication No.: US10995103B2Publication Date: 2021-05-04
- Inventor: Yihan Wang , Jiuyang Zhao
- Applicant: Shenzhen TargetRx, Inc.
- Applicant Address: CN Guangdong
- Assignee: Shenzhen TargetRx, Inc.
- Current Assignee: Shenzhen TargetRx, Inc.
- Current Assignee Address: CN Guangdong
- Agency: Wolf, Greenfield & Sacks, P.C.
- Priority: CN201610592116.8 20160725
- International Application: PCT/CN2017/094044 WO 20170724
- International Announcement: WO2018/019196 WO 20180201
- Main IPC: A61K31/69
- IPC: A61K31/69 ; A61K9/00 ; C07B59/00 ; C07F5/02 ; A61P13/12 ; A61P29/00 ; A61P35/00 ; A61P35/02 ; A61P37/00 ; A61P9/00 ; C07K5/06 ; C07H23/00
Abstract:
A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.
Public/Granted literature
- US20190263835A1 SUBSTITUTED BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND APPLICATION THEREOF Public/Granted day:2019-08-29
Information query
